...
首页> 外文期刊>BMC Anesthesiology >Can serum L-lactate, D-lactate, creatine kinase and I-FABP be used as diagnostic markers in critically ill patients suspected for bowel ischemia
【24h】

Can serum L-lactate, D-lactate, creatine kinase and I-FABP be used as diagnostic markers in critically ill patients suspected for bowel ischemia

机译:血清L-乳酸,D-乳酸,肌酸激酶和I-FABP可以用作疑似肠缺血的重症患者的诊断标志吗

获取原文
           

摘要

Background The prognostic value of biochemical tests in critically ill patients with multiple organ failure and suspected bowel ischemia is unknown. Methods In a prospective observational cohort study intensive care patients were included when the attending intensivist considered intestinal ischemia in the diagnostic workup at any time during intensive care stay. Patients were only included once. When enrolment was ended each patient was classified as ‘proven intestinal ischemia’, ‘ischemia likely’, ‘ischemia unlikely’ or ‘no intestinal ischemia’. Proven intestinal ischemia was defined as the gross disturbance of blood flow in the bowel, regardless of extent and grade. Classification was based on reports from the operating surgeon, pathology department, endoscopy reports and CT-scan. Lactate dehydrogenase (LDH), creatine kinase (CK), alanine aminotransferase (ALAT), L-lactate were available for the attending physician. D-lactate and intestinal fatty acid binding protein (I-FABP) were analysed later in a batch. I-FABP was only measured in patients with proven ischemia or no ischemia. Results For 44 of the 120 included patients definite diagnostic studies were available. 23/44 patients (52%) had proven intestinal ischemia as confirmed by surgery, colonoscopy, autopsy and/or histopathological findings. LDH in these patients was 285 U/l (217–785) vs 287 U/l (189–836) in no-ischemia; p?=?0.72. CK was 226 U/l in patients with proven ischemia (126–2145) vs 347 U/l (50–1427), p?=?0.88. ALAT was 53 U/l (18–300) vs 34 U/l (14–34), p-0,56. D-lactate 0.41 mmol/l (0.11-0.75) vs 0.56 mmol/l (0.27-0.77), p?=?0.46. L-lactate 3.5 mmol/l (2.2-8.4) vs 2.6 mmol/l (1.7-3.9), p?=?0.09. I-FABP 2872 pg/ml (229–4340) vs 1020 pg/ml (239–5324), p?=?0.98. Patient groups proven and likely ischemia together compared to unlikely and no-ischemia together showed significant higher L-lactate (p?=?0.001) and higher D-lactate (p?=?0.003). Conclusions Measurement of LDH, CK, and ALAT did not discriminate critically ill patients with proven intestinal ischemia from those with definite diagnosis no-ischemia. However, L-lactate and D-lactate levels were higher in patients with proven or likely ischemia and need further study just as I-FABP.
机译:背景生化检查对多器官功能衰竭和可疑肠缺血的危重患者的预后价值尚不清楚。方法在一项前瞻性观察性队列研究中,当重症监护病房住院期间的任何时候,主治医师在诊断性检查中考虑肠道缺血时,均纳入重症监护患者。患者仅被纳入一次。登记结束后,每位患者被分类为“已证实的肠缺血”,“可能的缺血”,“不太可能的缺血”或“没有肠缺血”。经证明的肠缺血定义为肠中血流的严重紊乱,无论程度和等级如何。分类基于手术医生,病理科的报告,内窥镜检查报告和CT扫描。乳酸脱氢酶(LDH),肌酸激酶(CK),丙氨酸转氨酶(ALAT),L-乳酸可供主治医师使用。稍后分批分析D-乳酸和肠脂肪酸结合蛋白(I-FABP)。 I-FABP仅在已证实缺血或无缺血的患者中进行测量。结果在120​​名患者中,有44名获得了明确的诊断研究。通过手术,结肠镜检查,尸检和/或组织病理学检查证实,有23/44例患者(52%)证实了肠缺血。这些患者的LDH为285 U / l(217-785),无缺血时为287 U / l(189-836)。 p≥0.72。在已证实缺血的患者中,CK为226 U / l(126–2145)与347 U / l(50–1427),p?=?0.88。 ALAT为53 U / l(18-300)比34 U / l(14-34),p-0,56。 D-乳酸酯为0.41mmol / l(0.11-0.75)对0.56mmol / l(0.27-0.77),p = 0.46。 L-乳酸盐为3.5mmol / l(2.2-8.4)对2.6mmol / l(1.7-3.9),p = 0.09。 I-FABP 2872 pg / ml(229–4340)vs 1020 pg / ml(239–5324),p?=?0.98。与不可能和没有缺血一起证实和可能缺血的患者组相比,L-乳酸含量显着较高(p = 0.001)和D-乳酸含量较高(p = 0.003)。结论LDH,CK和ALAT的测定不能将确诊为肠缺血的重症患者与确诊为非缺血的患者区分开。但是,在已证实或可能缺血的患者中,L-乳酸和D-乳酸的水平较高,与I-FABP一样需要进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号